BC
ADPT icon

Bridgefront Capital’s Adaptive Biotechnologies ADPT Stock Holding History

Bridgefront Capital’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-45,115
Closed -$626K – 493
2026
Q1 		$626K Buy
45,115
+31,965
+243% +$509K 0.16% 218
2025
Q4 		$214K Sell
13,150
-4,799
-27% -$78.3K 0.05% 443
2025
Q3 		$269K Sell
17,949
-4,289
-19% -$52.3K 0.08% 433
2025
Q2 		$259K Buy
22,238
+8,830
+66% +$80.2K 0.07% 479
2025
Q1 		$99.6K Buy
13,408
+115
+0.9% +$884 0.03% 583
2024
Q4 		$79.7K Buy
+13,293
New +$73.3K 0.03% 546
2021
Q1 		– Sell
-4,746
Closed -$281K – 646
2020
Q4 		$281K Buy
+4,746
New +$245K 0.1% 394

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Bridgefront Capital's ADPT Position: Q2 2026 in Review

Bridgefront Capital sold out of Adaptive Biotechnologies (ADPT) in Q2 2026, closing a stake of 45,115 shares — an estimated $626K sold.

Bridgefront Capital first reported a position in ADPT in Q4 2020 and held it in 7 quarters. The position peaked at $626K in Q1 2026. 300 funds tracked by Wall St. Rank hold ADPT as of Q2 2026.

  • Bridgefront Capital reported no remaining Adaptive Biotechnologies position as of Q2 2026 after selling out during the quarter.
  • Bridgefront Capital sold 45,115 Adaptive Biotechnologies shares in Q2 2026, an estimated $626K.
  • Bridgefront Capital first reported a position in Adaptive Biotechnologies in Q4 2020 and held it in 7 quarters.
  • Bridgefront Capital's Adaptive Biotechnologies position peaked at $626K in Q1 2026.
  • 300 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q2 2026.

Based on Bridgefront Capital's 13F filing for Q2 2026, filed 14 Aug 2026.